Launch week offerEnds in00h00m00s

annual Promonthly Pro

Diana Gibb

Has grant

Programme Leader

University College London

United Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Recent Grants

Grant: Close

A randomized trial of dolutegravir (DTG) based antiretroviral therapy vs standard of care (SOC) in children with HIV infection starting first line or switching to second line ART (ODYSSEY Longer Term Follow Up)

Open Date: 2021-01-01

Close Date: 2024-12-01

Grant: Close

A randomized trial of dolutegravir (DTG) based antiretroviral therapy vs standard of care (SOC) in children with HIV infection starting first line or switching to second line ART (ODYSSEY - FDA)

Open Date: 2021-01-01

Close Date: 2024-12-01

Grant: Close

Better Evidence and Formulations for Improved MDR-TB Treatment for Children

Open Date: 2019-10-01

Close Date: 2024-03-01

Grant: Close

MICA: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME)

Open Date: 2019-07-01

Close Date: 2025-04-30

Grant: Close

Severe Malaria Africa – A consortium for Research and Trials (SMAART)

Open Date: 2019-06-30

Close Date: 2023-06-30

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (27)

Sophie Uyoga

KEMRI-Wellcome Trust Research Programme

Diana Gibb

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (20)

Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial

Pharmacokinetic modeling to support WHO-weight band dosing of a new pediatric darunavir/ritonavir (120/20 mg) fixed-dose combination tablet for children at least 3 years old and weighing 10 to less than 35 kg

Computer-aided detection for radiological disease severity classification on chest radiograph in children with intra-thoracic tuberculosis

Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial

Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial

Intravenous Artesunate and Artemisinin-Resistant Severe Malaria in Uganda

CMV viraemia is associated with mortality among children with HIV starting antiretroviral therapy in sub-Saharan Africa

Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial.

Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in Uganda

Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda [version 2; peer review: 1 approved, 2 approved with reservations]

Severe Malaria A Research and Trials consortium - Multisite Adaptive Platform (SMAART MAP) Trial Protocol [version 1; peer review: 1 approved]

Oral rehydration for severe malnutrition in children with moderate and severe dehydration (GASTROSAM): a phase 2, open-label, superiority randomised controlled trial

Synthesis and Standardization of Outcomes in Severe Malaria Treatment Trials: Protocol for the Development of a Core Outcome Set (the COSSMaT Study)

Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV

The Utility of a Three-gene Host Response to Discriminate Tuberculous Meningitis From Other Infections in Children

A clinical practice guideline for tuberculous meningitis

Bone mineral density among children living with HIV failing first-line anti-retroviral therapy in Uganda: A sub-study of the CHAPAS-4 trial (Vol 20, e0288877, 2023)

Pharmacokinetics of lopinavir/ritonavir in second-line treatment of children living with HIV in the CHAPAS-4 trial

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV

Collaborators (27)

Sophie Uyoga

Deborah Ford

Paul Revill

James A. Seddon

Elizabeth Chappell

Catriona Waitt

Catherine Orrell

Ronald Tonui

Nicholas Day

Roisin Connon

Srini Bandi

Sharon B Love

Kathryn Maitland

Melissa Conrad

Marc Georges Jean Lallemant

Kelly E. Dooley

Paolo Denti

Robert Wilkinson

Carlo Giaquinto

James Scriven

Thomas Williams

Ewelina Rogozińska

Annabelle South

Seef Abdalla

Megan Palmer

A Sarah Walker

Elizabeth C George

Make your next move.